Uddin Mohammad A, Akhter Mohammad S, Kubra Khadeja-Tul, Siejka Agnieszka, Barabutis Nektarios
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA 71201, United States of America.
Department of Clinical Endocrinology, Medical University of Lodz, Lodz, Poland.
Exp Gerontol. 2021 Mar;145:111197. doi: 10.1016/j.exger.2020.111197. Epub 2020 Dec 10.
Senior individuals are more susceptible to the irreversible outcomes of endothelial barrier dysfunction, the hallmark of Acute Respiratory Distress Syndrome (ARDS). The Severe Acute Respiratory Syndrome Coronovirus 2 (SARS-CoV-2) - inflicted ARDS delivers the devastating outcomes of the COVID-19 worldwide. Endothelial hyperpermeability has been associated with both the progression and establishment of the COVID-19 - related respiratory failure. In the present study we investigated the in vitro effects of Metformin in the permeability of bovine pulmonary artery endothelial cells. Our preliminary results suggest that moderate doses (0.1, 0.5, 1.0 mM) of this anti-diabetic agent enhance the vascular barrier integrity, since it produces an increase in the transendothelial resistance of endothelial monolayers. Thus, we speculate that Metformin may deliver a new therapeutic possibility in ARDS, alone or in combination with other barrier enhancers.
老年人更容易受到内皮屏障功能障碍不可逆后果的影响，而内皮屏障功能障碍是急性呼吸窘迫综合征（ARDS）的标志。严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引发的ARDS在全球范围内导致了COVID-19的毁灭性后果。内皮细胞高通透性与COVID-19相关呼吸衰竭的进展和发生都有关联。在本研究中，我们调查了二甲双胍对牛肺动脉内皮细胞通透性的体外影响。我们的初步结果表明，这种抗糖尿病药物的中等剂量（0.1、0.5、1.0 mM）可增强血管屏障的完整性，因为它使内皮细胞单层的跨内皮电阻增加。因此，我们推测二甲双胍可能为ARDS提供一种新的治疗可能性，无论是单独使用还是与其他屏障增强剂联合使用。
